← Leaderboards
Douglas V Faller
Boston University Medical Campus
$14,088,389
Attributed
$19,052,331
Total exposure
17
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$19,052,331 · 17
By mechanism
R01$5,743,697 · 4
R33$5,206,823 · 1
R25$2,117,649 · 1
R42$1,647,144 · 2
R21$1,583,967 · 3
T32$1,254,673 · 1
Top collaborators
- Bennett B Goldberg12 shared
- Kevin Kuo3 shared
- Susan P Perrine3 shared
- Sylvia T Singer3 shared
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Susan P Perrine$12,101,972
- Angela Mei-Tin Leung$643,681
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularMalignant NeoplasmsTumorMediatingNeoplastic CellToxic EffectApoptosisCancer CellFutureSignal TransductionGenesCancer PreventionStructureMedicalCellsGlobal HealthPublic Health RelevanceRadiation TherapyButyratesMutationMalignant - DescriptorProgramsSignal PathwaySpecificity
Grant awards (63)
Development of a Clinical Hemoglobin Modulator$1,630,002
R33 · FY2022 · HL
Development of a Clinical Hemoglobin Modulator$1,843,809
R33 · FY2021 · HL
Development of a Clinical Hemoglobin Modulator$1,733,012
R33 · FY2020 · HL
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer$349,702
R25 · FY2014 · CA
Non-Oncogene Addiction as a Targeted Therapy for Pancreatic Cancer$197,693
R21 · FY2014 · CA · contact PI
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer$45,144
R25 · FY2014 · CA
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer$32,724
R25 · FY2014 · CA
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer$377,616
R25 · FY2013 · CA
Mechanisms of Action and Signaling by Steroid Hormone Antagonists$237,315
R01 · FY2013 · CA · contact PI
Non-Oncogene Addiction as a Targeted Therapy for Pancreatic Cancer$178,024
R21 · FY2013 · CA · contact PI
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer$45,144
R25 · FY2013 · CA
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer$32,724
R25 · FY2013 · CA
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer$338,296
R25 · FY2012 · CA
Mechanisms of Action and Signaling by Steroid Hormone Antagonists$252,463
R01 · FY2012 · CA · contact PI
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer$45,144
R25 · FY2012 · CA
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer$45,144
R25 · FY2012 · CA
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer$32,724
R25 · FY2012 · CA
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer$385,470
R25 · FY2011 · CA
Mechanisms of Action and Signaling by Steroid Hormone Antagonists$252,463
R01 · FY2011 · CA · contact PI
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer$387,817
R25 · FY2010 · CA
Mechanisms of Action and Signaling by Steroid Hormone Antagonists$260,271
R01 · FY2010 · CA · contact PI
Inducing Chromosomal Damage Responses in Pancreatic Cancer$214,500
R21 · FY2010 · CA · contact PI
Ras Oncoprotein-Targeted Therapy for Cancer$302,435
R01 · FY2009 · CA · contact PI
Development of an Oncogene-Targeted Therapeutic$271,227
R41 · FY2009 · CA · contact PI
Mechanisms of Action and Signaling by Steroid Hormone Antagonists$260,271
R01 · FY2009 · CA · contact PI
Inducing Chromosomal Damage Responses in Pancreatic Cancer$178,750
R21 · FY2009 · CA · contact PI
Ras Oncoprotein-Targeted Therapy for Cancer$56,604
R01 · FY2009 · CA · contact PI
Ras Oncoprotein-Targeted Therapy for Cancer$302,435
R01 · FY2008 · CA · contact PI
Ras Oncoprotein-Targeted Therapy for Cancer$54,979
R01 · FY2008 · CA · contact PI
Ras Oncoprotein-Targeted Therapy for Cancer$302,435
R01 · FY2007 · CA · contact PI
Signal Transduction by Androgen in Prostate Cells$251,136
R01 · FY2007 · CA · contact PI
Signal Transduction by Androgen in Prostate Cells$54,031
R01 · FY2007 · CA · contact PI
Ras Oncoprotein-Targeted Therapy for Cancer$49,449
R01 · FY2007 · CA · contact PI
Ras Oncoprotein-Targeted Therapy for Cancer$311,467
R01 · FY2006 · CA · contact PI
Signal Transduction by Androgen in Prostate Cells$258,636
R01 · FY2006 · CA · contact PI
Ras Oncoprotein-Targeted Therapy for Cancer$318,963
R01 · FY2005 · CA
Signal Transduction by Androgen in Prostate Cells$264,860
R01 · FY2005 · CA
Development of a Ras-Targeted Cancer Therapeutic$282,250
R41 · FY2004 · CA
Signal Transduction by Androgen in Prostate Cells$264,860
R01 · FY2004 · CA
CONTROL OF CELL GROWTH BY SHORT-CHAIN FATTY ACIDS$256,725
R01 · FY2004 · CA
CONTROL OF CELL GROWTH BY SHORT-CHAIN FATTY ACIDS$43,418
R01 · FY2004 · CA
Oral Therapeutic for Inducing Fetal Hemoglobin$450,000
R42 · FY2003 · HL
Oral Therapeutics for Viral Malignancies$373,572
R42 · FY2003 · CA
ONCOBIOLOGY TRAINING PROGRAM$367,595
T32 · FY2003 · CA
CONTROL OF CELL GROWTH BY SHORT-CHAIN FATTY ACIDS$256,725
R01 · FY2003 · CA
Oral Therapeutic for Beta-Thalassemia$182,312
R41 · FY2003 · DK
CONTROL OF CELL GROWTH BY SHORT-CHAIN FATTY ACIDS$38,844
R01 · FY2003 · CA
Oral Therapeutic for Inducing Fetal Hemoglobin$450,000
R42 · FY2002 · HL
ANTI VIRAL THERAPEUTIC FOR EBV MALIGNANCIES$407,500
R21 · FY2002 · CA
Oral Therapeutics for Viral Malignancies$373,572
R42 · FY2002 · CA
ONCOBIOLOGY TRAINING PROGRAM$349,334
T32 · FY2002 · CA
CONTROL OF CELL GROWTH BY SHORT-CHAIN FATTY ACIDS$256,725
R01 · FY2002 · CA
CANCER RESEARCH CENTER$156,412
P20 · FY2002 · CA
ANTI VIRAL THERAPEUTIC FOR EBV MALIGNANCIES$407,500
R21 · FY2001 · CA
CANCER RESEARCH CENTER$306,270
P20 · FY2001 · CA
CONTROL OF CELL GROWTH BY SHORT-CHAIN FATTY ACIDS$256,725
R01 · FY2001 · CA
ONCOBIOLOGY TRAINING PROGRAM$230,357
T32 · FY2001 · CA
ARGININE BUTYRATE FOR TREATMENT OF LEG ULCER IN PATIENTS WITH SICKLE CELL DISEASE$0
M01 · FY2001 · RR
CONTROL OF CELL GROWTH BY ONCOGENES$322,737
R01 · FY2000 · CA
ONCOBIOLOGY TRAINING PROGRAM$307,387
T32 · FY2000 · CA
CANCER RESEARCH CENTER$299,907
P20 · FY2000 · CA
CONTROL OF CELL GROWTH BY SHORT-CHAIN FATTY ACIDS$256,725
R01 · FY2000 · CA
ARGININE BUTYRATE THERAPY--LEG ULCER IN SICKLE CELL DISE$0
M01 · FY2000 · RR